While infusion pumps are the most widely deployed connected medical devices, they are not the leading cause of security alerts.
The US Food and Drug Administration (FDA) on Tuesday finalized a rule that requires medical device clinical investigations conducted outside the US to flexibly conform with good clinical practice (GCP) standards.
Ddu (www.drugdu.com) is the world's first B2B online platform focused on the cross-border trade of pharmaceuticals and medical devices. As a pioneer in the industry, Ddu is committed to accelerating the circulation of the pharmaceutical and medical device trade around the world, making it simpler, easier and more efficient.
Have you made your schedule for 2018? Take some time to consider your options and see what Ddu has planned this February!
It is a disturbing, but true fact that medical devices are hacked. Medical devices have inbuilt software, and hackers try to breach this. Medical device cybersecurity is thus critical, because lack of it can bring harm to patients who use medical devices that come with software built into them.
With the recent, highly publicized incidents of identity theft, ransomware and malware attacks directed at healthcare facilities, the medical device community is on high-security alert.
Healthcare organizations should use risk management processes to ensure the security of health information and protect against the vulnerabilities stemming from the Spectre and Meltdown threats.
The Arab Health Exhibition 2018 will be held at the Dubai International Convention & Exhibition Centre from January 29th to February 1st, 2018. Ddu, the leading global pharmaceutical & medical device B2B online platform, will once again attend the exhibition, showcasing the changes that the Internet has brought to cross-border medical trade to the visitors in Dubai, as well as our global audience.
If 2017 was about ransomware attacks, 2018 will be about cyber attacks on the Internet of Things (aka medical devices).
Alveo Technologies, Inc., ("Alveo" or "the Company") whose mission it is to create affordable and accessible infectious disease diagnostic devices, announced the closing of a $38 million Series A financing raised by Maxim Merchant Capital, a division of Maxim Group LLC. The round was oversubscribed and included existing and new investors. The offering proceeds will be used to advance the optimization and commercialization of Alveo's rapid diagnostic platform for infectious diseases.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.